Navigation Links
Millennium Ranks in the Top 10 Best Biopharma Employers in the World by Science Magazine
Date:10/9/2008

CAMBRIDGE, Mass., Oct. 9 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced it has been named among the best biopharmaceutical companies in the world, according to Science magazine's annual survey of Top Employers in the biotechnology, biopharmaceutical, pharmaceutical and related industries. With a 2008 ranking of eighth, the Company is in the top ten for the first time, moving up from a 2007 ranking of 14.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080827/NEW076LOGO )

"This top ten ranking underscores Millennium's commitment not only to breakthrough science, but also to its employees and overall working environment," said Stephen Gansler, Senior Vice President, Human Resources, Millennium. "It is now more important than ever for us to keep up this positive work culture as we recruit for the hundreds of new additions over the next few months."

Respondents to the web-based survey were asked to rate companies based on 23 driving characteristics, including financial strength, easy adaptation to change and a research-driven environment. The 2008 survey sought to identify the companies with the best reputations as employers, based on nearly 4,000 survey responses from readers of Science and other respondents in industry. Twenty percent of the respondents came from outside the United States, primarily Western Europe, and 92 percent worked in private industry. For the complete business office feature with individual company rankings, please visit: http://sciencecareers.sciencemag.org/career_magazine/previous_issues/articl es/ 2008_10_10/science.opms.r0800061.

Millennium was acquired by Takeda Pharmaceutical Company Limited in May, 2008.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium research, development and commercialization activities are focused in oncology. Additional information about Millennium is available through its website, http://www.millennium.com.

Editor's Note: This press release is also available under the Media section of the Company's website at: http://www.millennium.com

Media Contact:

Manisha Pai

(617)551-7877

manisha.pai@mpi.com


'/>"/>
SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Mark C. Mirken Named New CEO and Chairman of the Board of Millennium Biotechnologies, Inc.
2. Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBCs Drug Discovery & Development of Innovative Therapeutics Conference
3. Millennium Biotechnologies Announces an Increased Annualized Purchase Commitment Totaling $5.8M from Provider Services, Inc.
4. Takeda Successfully Completes Tender Offer for Millennium Pharmaceuticals, Inc. and Announces Subsequent Offering Period
5. Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion
6. Millennium Announces VELCADE(R) (Bortezomib) for Injection First-Quarter 2008 U.S. Net Sales
7. Millennium Announces $200,000 Purchase Order From Greek Distributor
8. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
9. Millennium Over-Delivers on 2007 Goals and Financial Guidance
10. Millennium Biotechnologies Group Reports 40% Sales Increase for Resurgex Product Line in Greek Market
11. Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of ... higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... of the cuvette holder. , FireflySci has developed several Agilent flow cell product ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology:
(Date:5/24/2016)... Ampronix facilitates superior patient care by providing unparalleled technology to leaders of the medical ... premium product recently added to the range of products distributed by Ampronix. ... ... ... Ampronix News ...
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
Breaking Biology News(10 mins):